

Samantha Galluzzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2300695/publications.pdf>

Version: 2024-02-01

87
papers

5,273
citations

116194
36
h-index

100535
70
g-index

87
all docs

87
docs citations

87
times ranked

9017
citing authors

#	ARTICLE	IF	CITATIONS
1	Brain network modulation in Alzheimer's and frontotemporal dementia with transcranial electrical stimulation. <i>Neurobiology of Aging</i> , 2022, 111, 24-34.	1.5	16
2	Psychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2022, Publish Ahead of Print, .	0.6	3
3	Norms for Automatic Estimation of Hippocampal Atrophy and a Step Forward for Applicability to the Italian Population. <i>Frontiers in Neuroscience</i> , 2021, 15, 656808.	1.4	4
4	CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	1.5	11
5	Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 817-826.	1.4	6
6	Age at onset reveals different functional connectivity abnormalities in prodromal Alzheimer's disease. <i>Brain Imaging and Behavior</i> , 2020, 14, 2594-2605.	1.1	17
7	Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 152.	3.0	7
8	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. <i>Frontiers in Aging Neuroscience</i> , 2020, 11, 366.	1.7	17
9	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. <i>Frontiers in Neurology</i> , 2020, 11, 1021.	1.1	10
10	Predicting and Tracking Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 3-14.	1.2	18
11	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
12	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85
13	Biomarker Matrix to Track Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 49-58.	1.2	8
14	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 383-394.	1.2	14
15	Plasma A β 42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnesic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 37-48.	1.2	23
16	Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	1.2	34
17	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 280-292.	0.4	246
18	Association of postoperative delirium with markers of neurodegeneration and brain amyloidosis: a pilot study. <i>Neurobiology of Aging</i> , 2018, 61, 93-101.	1.5	18

#	ARTICLE	IF	CITATIONS
19	P4â€098: ASSOCIATION BETWEEN COGNITIVE RESERVE AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1474.	0.4	0
20	P4â€077: BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG^{Â®} TEST ENABLE STRATIFICATION OF PREâ€DEMENTIA ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1464.	0.4	0
21	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. <i>Alzheimer's and Dementia</i> , 2017, 13, 1013-1023.	0.4	33
22	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnesic mild cognitive impairment (MCI). <i>Neurobiology of Aging</i> , 2017, 53, 1-10.	1.5	59
23	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	1.5	27
24	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.4	113
25	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.4	108
26	The Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2017, 13, 624-633.	0.4	143
27	Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. <i>Neurobiology of Aging</i> , 2017, 49, 60-68.	1.5	870
28	[P4â€157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1319.	0.4	4
29	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 151-164.	1.2	7
30	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€European <sc>ADNI</sc> studyâ€™. <i>Journal of Internal Medicine</i> , 2016, 279, 576-591.	2.7	64
31	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. <i>JAMA Neurology</i> , 2016, 73, 1417.	4.5	84
32	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. <i>Neurodegenerative Diseases</i> , 2016, 16, 111-117.	0.8	6
33	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 84-90.	0.9	10
34	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , 2016, 108, 128-135.	2.0	23
35	Brain atrophy in Alzheimerâ€™s Disease and aging. <i>Ageing Research Reviews</i> , 2016, 30, 25-48.	5.0	507
36	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimerâ€™s Disease. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1631-e1638.	1.1	38

#	ARTICLE	IF	CITATIONS
37	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	1.2	34
38	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. <i>NeuroImage: Clinical</i> , 2015, 7, 34-42.	1.4	85
39	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.5	122
40	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnesic MCI: An European Alzheimer's Disease Consortium (EADC) Project. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 815-826.	1.2	67
41	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.4	56
42	Hippocampal atrophy in people with memory deficits: results from the population-based IPREA study. <i>International Psychogeriatrics</i> , 2014, 26, 1067-1081.	0.6	19
43	Medial temporal atrophy in early and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2004-2012.	1.5	59
44	Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects. <i>NeuroImage</i> , 2014, 101, 390-403.	2.1	99
45	P3-101: CROSS-SECTIONAL BIOMARKER CHARACTERIZATION OF MILD COGNITIVE IMPAIRMENT PATIENTS IN WP5 PHARMACOG/E-ADNI STUDY. , 2014, 10, P665-P665.		1
46	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. <i>Journal of Neurology</i> , 2013, 260, 640-650.	1.8	50
47	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013, 9, 677-686.	0.4	51
48	Distinct cerebrospinal fluid amyloid β peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. <i>Electrophoresis</i> , 2012, 33, 3738-3744.	1.3	34
49	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. <i>Alzheimer's and Dementia</i> , 2012, 8, 520-527.	0.4	32
50	Norms for Imaging Markers of Brain Reserve. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 623-633.	1.2	18
51	APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. <i>NeuroImage</i> , 2011, 55, 909-919.	2.1	116
52	Autonomic dysfunction in mild cognitive impairment: a transcranial Doppler study. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 403-409.	1.0	15
53	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 77-83.	0.9	38
54	White Matter Damage in Alzheimer Disease and Its Relationship to Gray Matter Atrophy. <i>Radiology</i> , 2011, 258, 853-863.	3.6	263

#	ARTICLE	IF	CITATIONS
55	Diagnosis Disclosure of Prodromal Alzheimer Disease-Ethical Analysis of Two Cases. Canadian Journal of Neurological Sciences, 2010, 37, 67-75.	0.3	22
56	Preliminary Evidence of Validity of the Revised Criteria for Alzheimer Disease Diagnosis. Alzheimer Disease and Associated Disorders, 2010, 24, 108-114.	0.6	13
57	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology, 2010, 257, 2004-2014.	1.8	44
58	Regional atrophy of transcallosal prefrontal connections in cognitively normal <i>APOE</i> ϵ 4 carriers. Journal of Magnetic Resonance Imaging, 2009, 29, 1021-1026.	1.9	36
59	Cardiac Autonomic Dysfunction Is Associated With White Matter Lesions in Patients With Mild Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1312-1315.	1.7	30
60	The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clinical and Experimental Research, 2009, 21, 266-276.	1.4	31
61	Mapping the effect of <i>APOE</i> ϵ 4 on gray matter loss in Alzheimer's disease in vivo. NeuroImage, 2009, 45, 1090-1098.	2.1	71
62	Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer's and Dementia, 2009, 5, 307-317.	0.4	80
63	Aging. Neurological Sciences, 2008, 29, 296-300.	0.9	35
64	White matter lesions in the elderly: Pathophysiological hypothesis on the effect on brain plasticity and reserve. Journal of the Neurological Sciences, 2008, 273, 3-9.	0.3	62
65	Hippocampal shape differences in dementia with Lewy bodies. NeuroImage, 2008, 41, 699-705.	2.1	47
66	Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer's Disease – Data from the ICTUS Study. Dementia and Geriatric Cognitive Disorders, 2008, 26, 314-322.	0.7	8
67	Association of Blood Pressure and Genetic Background With White Matter Lesions in Patients With Mild Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 510-517.	1.7	8
68	Vascular damage and EEG markers in subjects with mild cognitive impairment. Clinical Neurophysiology, 2007, 118, 1866-1876.	0.7	66
69	The effect of white matter lesions on cognition in the elderly"small but detectable. Nature Clinical Practice Neurology, 2007, 3, 620-627.	2.7	104
70	Prescription patterns and efficacy of drugs for patients with dementia: physicians's perspective in Italy. Aging Clinical and Experimental Research, 2007, 19, 349-355.	1.4	12
71	Validation Study of the Three-Objects-Three-Places Test: A Screening Test for Alzheimer's Disease. Experimental Aging Research, 2006, 32, 395-410.	0.6	14
72	Topographic correspondence between white matter hyperintensities and brain atrophy. Journal of Neurology, 2006, 253, 919-927.	1.8	28

#	ARTICLE	IF	CITATIONS
73	Distinctive Clinical Features of Mild Cognitive Impairment with Subcortical Cerebrovascular Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 196-203.	0.7	96
74	Brain volumes in healthy adults aged 40 years and over: a voxel-based morphometry study. <i>Aging Clinical and Experimental Research</i> , 2005, 17, 329-336.	1.4	54
75	Visual assessment of medial temporal atrophy on MR films in Alzheimer's disease: comparison with volumetry. <i>Aging Clinical and Experimental Research</i> , 2005, 17, 8-13.	1.4	68
76	Prescription and choice of diagnostic imaging by physician specialty in Alzheimer's Centers (UnitÀ di Tj ETQq0 0 0 rgBT /Overlock 14-19.	1.4	6
77	Prescription practices of diagnostic imaging in dementia: a survey of 47 Alzheimer's Centres in Northern Italy. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 577-585.	1.3	8
78	The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. <i>Neurobiology of Aging</i> , 2003, 24, 95-103.	1.5	107
79	Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1371-1381.	0.9	69
80	Validation Study of a CT-Based Weighted Rating Scale for Subcortical Ischemic Vascular Disease in Patients with Mild Cognitive Deterioration. <i>European Neurology</i> , 2003, 49, 193-209.	0.6	36
81	Drug Treatment of REM Sleep Behavior Disorders in Dementia With Lewy Bodies. <i>International Psychogeriatrics</i> , 2003, 15, 377-383.	0.6	63
82	Hashimoto's Encephalopathy in the Elderly: Relationship to Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 175-179.	1.2	23
83	Development of a CT-based weighted rating scale for subcortical cerebrovascular disease sensitive to mild clinical symptoms. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 241-245.	0.3	1
84	Mild cognitive impairment with subcortical vascular features. <i>Journal of Neurology</i> , 2002, 249, 1423-1432.	1.8	149
85	An old nun with diabetes who should not have been moved from her nunnery. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 100-101.	1.3	2
86	No evidence for the involvement of interleukin 2 or the immunoglobulin heavy chain gene cluster in determining genetic susceptibility to multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 679-679.	0.9	14
87	Temporal lobe asymmetry in patients with Alzheimer's disease with delusions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 187-191.	0.9	63